NKTR
BEARISH
$81.26
Live
Nektar Therapeutics · NASDAQ
Target $128.12
(+57.7%)
$7.99
52W Range
$81.43
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 15, 2026
Market cap
$2.33B
P/E
N/A
ROE
-217.9%
Profit margin
-297.1%
Debt/Equity
1.66
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
NKTR exhibits catastrophic fundamental health, highlighted by a Piotroski F-Score of 0/9, indicating severe financial deterioration across all measured dimensions. Despite a massive 802.9% one-year price surge and 'Strong Buy' analyst ratings, the company suffers from declining revenue (-25.3% YoY), deep negative profit margins (-297.07%), and an extreme valuation (P/S of 42.21). The current stock price appears to be driven by speculative momentum or anticipated catalysts rather than any existing financial value. The disconnect between the deterministic health scores and the market price suggests a high-risk speculative bubble.
Key Strengths
Strong short-term liquidity with a Current Ratio of 4.97
Recent history of beating earnings estimates (3/4 last quarters)
Significant positive price momentum over the last 12 months
Strong analyst consensus with a target price of $128.12
High gross margin (100%) suggesting low cost of goods sold
Key Risks
Piotroski F-Score of 0/9 indicates critical financial weakness
Negative revenue growth (-25.3% YoY) suggests failing product traction
Extreme valuation multiples (P/B 18.43, P/S 42.21) are unsustainable
Deeply negative ROE (-217.94%) and Profit Margins
Bearish insider sentiment with consistent selling by the CEO and officers
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
11
Weak
5
30
20
0
0
AI Verdict
Speculative High-Risk
Key drivers: Piotroski 0/9, Negative Revenue Growth, Extreme P/S Ratio, Insider Selling
Confidence
95%
Value
5/100
Stock trades at a massive premium despite declining fundamentals.
Positives
No standout positives identified.
Watchpoints
- P/S of 42.21 is excessive
- P/B of 18.43 is extreme
- No Graham Number due to lack of earnings
Future
30/100
Future value is entirely dependent on binary biotech catalysts, not current growth rates.
Positives
- Analyst target price suggests 57% upside
- Recent EPS surprises are positive
Watchpoints
- Revenue growth is trending downward
- Operating margins remain deeply negative
Past
20/100
Long-term trend is destructive despite recent speculative spike.
Positives
- Recent 1Y price recovery
Watchpoints
- 5Y change is -72%
- Consistent history of losses
Health
0/100
Deterministic health scores are at the absolute minimum.
Positives
- High current ratio
Watchpoints
- Piotroski F-Score 0/9
- Negative ROE and ROA
Dividend
0/100
Non-dividend paying growth/speculative stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No capacity to pay dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$81.26
Analyst Target
$128.12
Upside/Downside
+57.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NKTR and closest competitors.
Updated 2026-04-14
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
Primary
|
-72.0% | +482.5% | +802.9% | +42.4% | +12.5% | +6.6% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
HTFL
Heartflow, Inc.
Peer
|
-10.1% | -10.1% | -10.1% | -19.5% | +21.3% | +8.5% |
|
APLS
Apellis Pharmaceuticals, Inc.
Peer
|
-59.8% | -70.9% | -22.3% | -23.8% | -15.1% | -5.6% |
|
DAWN
Day One Biopharmaceuticals, Inc.
Peer
|
-8.7% | +69.0% | +205.7% | +189.6% | +0.6% | +0.1% |
NKT
Nektar Therapeutics
Primary
5Y
-72.0%
3Y
+482.5%
1Y
+802.9%
6M
+42.4%
1M
+12.5%
1W
+6.6%
ATE
Alphatec Holdings, Inc.
Peer
5Y
+4.7%
3Y
+20.4%
1Y
+33.9%
6M
+44.4%
1M
-24.8%
1W
-11.9%
HTF
Heartflow, Inc.
Peer
5Y
-10.1%
3Y
-10.1%
1Y
-10.1%
6M
-19.5%
1M
+21.3%
1W
+8.5%
APL
Apellis Pharmaceuticals, Inc.
Peer
5Y
-59.8%
3Y
-70.9%
1Y
-22.3%
6M
-23.8%
1M
-15.1%
1W
-5.6%
DAW
Day One Biopharmaceuticals, Inc.
Peer
5Y
-8.7%
3Y
+69.0%
1Y
+205.7%
6M
+189.6%
1M
+0.6%
1W
+0.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-7.23
PEG Ratio
N/A
P/B Ratio
18.43
P/S Ratio
42.21
EV/Revenue
40.45
EV/EBITDA
-17.22
Market Cap
$2.33B
Profitability
Profit margins and return metrics
Profit Margin
-297.07%
Operating Margin
-87.54%
Gross Margin
100.0%
ROE
-217.94%
ROA
-27.98%
Growth
Revenue and earnings growth rates
Revenue Growth
-25.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-25.25%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.66
High debt
Current Ratio
4.97
Strong
Quick Ratio
4.62
Excellent
Cash/Share
$8.57
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
100.0%
Op. Margin
-87.5%
Net Margin
-165.4%
Total Assets
$0.3B
Liabilities
$0.2B
Equity
$0.1B
Debt/Equity
2.12x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-12
$-1.29
+63.1% surprise
2025-11-06
$-1.87
+33.0% surprise
2025-08-07
$-2.95
+2.8% surprise
Healthcare Sector Comparison
Comparing NKTR against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-217.94%
This Stock
vs
-101.52%
Sector Avg
+114.7%
(Excellent)
Profit Margin
-297.07%
This Stock
vs
-12.47%
Sector Avg
+2282.4%
(Superior)
Debt to Equity
1.66
This Stock
vs
3.4
Sector Avg
-51.3%
(Less Debt)
Revenue Growth
-25.3%
This Stock
vs
124.21%
Sector Avg
-120.4%
(Slower)
Current Ratio
4.97
This Stock
vs
4.56
Sector Avg
+9.1%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
BEARISH | $2.33B | - | -217.9% | -297.1% | $81.26 | |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | Compare |
|
HTFL
Heartflow, Inc.
|
BEARISH | $2.31B | - | -111.4% | -66.3% | $26.95 | Compare |
|
APLS
Apellis Pharmaceuticals, Inc.
|
BEARISH | $2.42B | 105.22 | 7.5% | 2.2% | $18.94 | Compare |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
NEUTRAL | $2.22B | - | -22.7% | -67.8% | $21.46 | Compare |
NKTR
Nektar Therapeutics
BEARISH
Mkt Cap
$2.3B
P/E
-
ROE
-217.9%
Price
$81.26
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | ROBIN HOWARD W | Chief Executive Officer | Sale | 423 | $30,879 |
| 2026-02-18 | ZALEVSKY JONATHAN | Officer | Sale | 180 | $13,140 |
| 2026-01-20 | ZALEVSKY JONATHAN | Officer | Sale | 3,867 | $137,936 |
| 2025-12-22 | ROBIN HOWARD W | Chief Executive Officer | Stock Award | 21,667 | - |
| 2025-12-22 | ZALEVSKY JONATHAN | Officer | Stock Award | 6,250 | - |
| 2025-11-25 | ROBIN HOWARD W | Chief Executive Officer | Sale | 2,207 | $119,796 |
| 2025-11-25 | ZALEVSKY JONATHAN | Officer | Sale | 1,157 | $62,802 |
| 2025-11-25 | WILSON MARK ANDREW | Officer | Sale | 630 | $34,196 |
| 2025-11-21 | ROBIN HOWARD W | Chief Executive Officer | Stock Award | 7,110 | - |
| 2025-11-21 | ZALEVSKY JONATHAN | Officer | Stock Award | 2,666 | - |
| 2025-11-21 | WILSON MARK ANDREW | Officer | Stock Award | 1,903 | - |
ROBIN HOWARD W
Chief Executive Officer
2026-02-18
423 shares
·
$30,879
ZALEVSKY JONATHAN
Officer
2026-02-18
180 shares
·
$13,140
ZALEVSKY JONATHAN
Officer
2026-01-20
3,867 shares
·
$137,936
ROBIN HOWARD W
Chief Executive Officer
2025-12-22
21,667 shares
ZALEVSKY JONATHAN
Officer
2025-12-22
6,250 shares
ROBIN HOWARD W
Chief Executive Officer
2025-11-25
2,207 shares
·
$119,796
ZALEVSKY JONATHAN
Officer
2025-11-25
1,157 shares
·
$62,802
WILSON MARK ANDREW
Officer
2025-11-25
630 shares
·
$34,196
ROBIN HOWARD W
Chief Executive Officer
2025-11-21
7,110 shares
ZALEVSKY JONATHAN
Officer
2025-11-21
2,666 shares
WILSON MARK ANDREW
Officer
2025-11-21
1,903 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
8 analysts
Wedbush
2026-03-24
Neutral
TD Cowen
2026-03-17
Buy
Citigroup
2026-03-16
Buy
Buy
B. Riley Securities
2026-02-23
Buy
Buy
HC Wainwright & Co.
2026-02-10
Buy
Buy
BTIG
2026-02-10
Buy
Buy
BTIG
2026-01-29
Buy
Buy
HC Wainwright & Co.
2025-12-16
Buy
Buy
BTIG
2025-12-16
Buy
Buy
Citigroup
2025-11-26
Buy
Past News Coverage
Recent headlines mentioning NKTR from our newsroom.
Newest → oldest
No matching news yet.